Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

Roshini Claire Anthony, one year ago

Patients with pancreatic adenocarcinoma (PDAC) given adjuvant chemotherapy (ACT) appeared to have better overall survival (OS) than those given adjuvant chemoradiation therapy (ACRT), according to new research.

Teriparatide may be ineffective in fracture healing, meta-analysis finds

4 months ago

There is no evidence supporting the efficacy of teriparatide for healing fractures despite having no adverse effect, according to a new meta-analysis. However, more high-quality studies are needed to yield more definitive conclusions about its effectiveness.

Databases including the Cochrane Library, Embase and PubMed were accessed using combinations of the following search terms: “hPTH (1-34),” “Parathar,” “Teriparatide Aventis Brand,” “Forteo,” “Fracture Healings,” “Teriparatide Lilly Brand,” and “Healing, Fracture,” among others.

Because the authors were not contacted for clarifications and additional information, only those that were completely published were included in the final study. No language restriction was applied to the search.

Inclusion criteria were as follows: study design being a randomized controlled trial, participants being adults with acute fractures and administered teriparatide, and teriparatide treatment being compared with a placebo treatment.

Studies that included participants who had histories of teriparatide or parathyroid hormone use, included participants that had contraindications to the drugs used in the study, weren’t randomized controlled trials or weren’t complete, or included participants with serum calcium levels above the reference limit were excluded from the analysis.

Information regarding authors, date of publication, characteristics of population, type of fracture, treatments administered, number of cases, duration of follow-up, rate of fracture healing, pain score, time of radiological healing of fracture and functional outcomes were retrieved. The primary endpoints of the study were the fracture healing rate and the time of fracture healing.

After applying the exclusion and inclusion criteria, five trials corresponding to a total of 380 patients were included in the analysis.

While the meta-analysis showed that teriparatide was associated with a significant improvement in terms of functioning after the fracture, no significant improvement was observed in pain reduction, healing rate of the fracture and radiographic healing of the fracture.

The data indicate a lack of evidence showing the efficacy of teriparatide in healing fractures. However, more studies of high quality are needed to make stronger conclusions.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

Roshini Claire Anthony, one year ago

Patients with pancreatic adenocarcinoma (PDAC) given adjuvant chemotherapy (ACT) appeared to have better overall survival (OS) than those given adjuvant chemoradiation therapy (ACRT), according to new research.